Loading...
Clinical trial data review of the combination FTD/TPI + bevacizumab in the treatment landscape of unresectable metastatic colorectal cancer
André, T. Van Cutsem, E. Taieb, J. Fakih, M. Prager, G. W. Ciardiello, F. Falcone, A. Saunders, Mark Amellal, N. Roby, L.
André, T.
Van Cutsem, E.
Taieb, J.
Fakih, M.
Prager, G. W.
Ciardiello, F.
Falcone, A.
Saunders, Mark
Amellal, N.
Roby, L.
Citations
Altmetric:
Abstract
Recommended first and second line treatments for unresectable metastatic colorectal cancer (mCRC) include fluorouracil-based chemotherapy, anti-vascular endothelial growth factor (VEGF)-based therapy, and anti-epidermal growth factor receptor-targeted therapies. In third line, the SUNLIGHT trial showed that trifluridine/tipiracil + bevacizumab (FTD/TPI + BEV) provided significant survival benefits and as such is now a recommended third line regimen in patients with refractory mCRC, irrespective of RAS mutational status and previous anti-VEGF treatment. Some patients are not candidates for intensive combination chemotherapy as first-line therapy due to age, low tumor burden, performance status and/or comorbidities. Capecitabine (CAP) + BEV is recommended in these patients. In the SOLSTICE trial, FTD/TPI + BEV as a first line regimen in patients not eligible for intensive therapy was not superior to CAP + BEV in terms of progression-free survival (PFS). However, in SOLSTICE, FTD/TPI + BEV resulted in similar PFS, overall survival, and maintenance of quality of life as CAP + BEV, with a different safety profile. FTD/TPI + BEV offers a possible first line alternative in patients for whom CAP + BEV is an unsuitable treatment. This narrative review explores and summarizes the clinical trial data on FTD/TPI + BEV.
Affiliation
Description
Date
2024
Publisher
Collections
Files
Keywords
Type
Article
Citation
André T, Van Cutsem E, Taieb J, Fakih M, Prager GW, Ciardiello F, et al. Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer. Curr Treat Options Oncol. 2024 Oct;25(10):1312-22. PubMed PMID: 39325367. Pubmed Central PMCID: PMC11485186. Epub 2024/09/26. eng.